‘Turbocharged artificial intelligence’ could personalize com
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.

The five-year survival rate for individuals with pediatric acute lymphoblastic leukemia is about 85 percent, however those who experience a recurrence generally have a poor prognosis and a bone marrow transplant is their only option for a permanent cure....

https://www.uclahealth.org/turbocharged-artificial-intelligence-could-personalize-combination-therapy-in-pediatric-leukemia
Like
Comment
Share